MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.39
+0.48
+1.27%
Opening 10:40 06/24 EDT
OPEN
38.12
PREV CLOSE
37.91
HIGH
38.77
LOW
37.99
VOLUME
224.83K
TURNOVER
--
52 WEEK HIGH
56.74
52 WEEK LOW
17.67
MARKET CAP
5.45B
P/E (TTM)
-14.7682
1D
5D
1M
3M
1Y
5Y
BRIEF-Tg Therapeutics Says On June 16, Board Appointed Laurence Charney As Lead Independent Director
reuters.com · 1d ago
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluating ublituximab, the Company’s investigational novel, glyco...
GlobeNewswire · 5d ago
TG Therapeutics reports preclinical data evaluating TG-1701 in B-cell malignancies
TG Therapeutics (TGTX) announces data from two presentations evaluating TG-1701 in B-cell malignancies. One presentation evaluated TG-1701 preclinically.Another included Phase 1 data as a monotherapy and as a triple therapy
Seekingalpha · 6d ago
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Company's investigational once-daily, oral BTK inhibitor, presented today during the 16 International Congress on Malignant Lymphoma (ICML). One prese...
GlobeNewswire · 6d ago
TG Therapeutics reports TG-1701 data in blood cancers at EHA 2021
TG Therapeutics (TGTX) announces data from TG-1701 as a monotherapy and as a triple therapy in combination with ublituximab and Ukoniq (umbralisib) in patients with front line or relapsed/refractory non-Hodgkin’s
Seekingalpha · 06/11 12:01
BRIEF-TG Therapeutics Announces Data From A Phase 1 Study Evaluating TG-1701
reuters.com · 06/11 11:03
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ(R) at the 2021 European Hematology Association Virtual Congress
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company's investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company's novel glycoengineered anti-CD20 m...
GlobeNewswire · 06/11 11:00
BRIEF-Tg Therapeutics Announces Data Presentations At The Upcoming 16 International Congress On Malignant Lymphoma
reuters.com · 06/09 11:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TGTX. Analyze the recent business situations of TG Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TGTX stock price target is 72.57 with a high estimate of 91.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 304
Institutional Holdings: 115.63M
% Owned: 81.39%
Shares Outstanding: 142.07M
TypeInstitutionsShares
Increased
86
11.93M
New
38
1.66M
Decreased
75
10.95M
Sold Out
48
2.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.84%
Pharmaceuticals & Medical Research
+1.55%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Michael Weiss
Chief Financial Officer/Treasurer/Secretary
Sean Power
Independent Director
Laurence Charney
Chief Technology Officer
Kelly Ross
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
William Kennedy
Independent Director
Sagar Lonial
No Data
About TGTX
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.